| Literature DB >> 31924199 |
Jennifer Ilo Van Nuil1,2, Thi Thanh Thuy Nguyen3, Thanh Nhan Le Nguyen4, Van Vinh Chau Nguyen5, Mary Chambers3,6, Thi Dieu Ngan Ta7, Laura Merson6,8, Thi Phuong Dung Nguyen3, Minh Tu Van Hoang9, Michael Parker10, Susan Bull10, Evelyne Kestelyn3,6.
Abstract
BACKGROUND: Within the research community, it is generally accepted that consent processes for research should be culturally appropriate and tailored to the context, yet researchers continue to grapple with what valid consent means within specific stakeholder groups. In this study, we explored the consent practices and attitudes regarding essential information required for the consent process within hospital-based trial communities from four referral hospitals in Vietnam.Entities:
Keywords: Clinical research; Consent; Research ethics; Trust; Vietnam; nghiên cứu
Year: 2020 PMID: 31924199 PMCID: PMC6954581 DOI: 10.1186/s12910-020-0445-z
Source DB: PubMed Journal: BMC Med Ethics ISSN: 1472-6939 Impact factor: 2.652
Characteristics of study participant stakeholders
| Age, median years, (IQR) | 33 (30, 40) |
| Gender, number (%) | |
| Women | 8 (57.1) |
| Men | 6 (42.9) |
| Study Role, number (%) | |
| Participant | 4 (28.6) |
| Patient representative | 10 (71.4) |
| Institution from where recruited, number (%) | |
| Infectious Disease Hospitals | 5 (35.7) |
| Children’s Hospitals | 6 (42.9) |
| Unknown | 3 (21.4) |
| Disease under study, number (%) | |
| Dengue | 14 (100.0) |
Characteristics of research stakeholders
| Age, median years (IQR) | 43 (32, 55) |
| Gender, number (%) | |
| Women | 12 (44.4) |
| Men | 15 (55.6) |
| Role, number (%) | |
| Physician | 13 (48.1) |
| Physician & EC member | 11 (40.7) |
| EC member | 2 (7.4) |
| Nurse | 1 (3.7) |
| Institution, number (%) | |
| Infectious Disease Hospital | 12 (44.4) |
| Children’s Hospital | 12 (44.4) |
| Medical Center | 1 (3.7) |
| Research Institute | 1 (3.7) |
| Ministry of Health | 1 (3.7) |
Ranking of essential elements of consent
| Research Stakeholders | Study Participants | Total | |
|---|---|---|---|
| Inclusion of the word research | |||
| Essential | 19 (70.4) | 10 (71.4) | 29 (70.7) |
| Neutral | 6 (22.2) | 2 (14.3) | 8 (19.5) |
| Non-essential | 2 (7.4) | 2 (14.3) | 4 (9.8) |
| Study purpose | |||
| Essential | 24 (88.9) | 13 (92.9) | 37 (90.2) |
| Neutral | 3 (11.1) | 1 (7.1) | 4 (9.8) |
| Non-essential | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Use of randomization | |||
| Missing | 0 | 2 | 2 |
| Essential | 8 (33.3) | 5 (41.7) | 13 (33.3) |
| Neutral | 8 (29.6) | 3 (25.0) | 11 (28.2) |
| Non-essential | 11 (37.0) | 4 (33.3) | 15 (38.5) |
| Study procedures | |||
| Essential | 19 (70.4) | 10 (71.4) | 29 (70.7) |
| Neutral | 7 (25.9) | 3 (21.4) | 10 (24.4) |
| Non-essential | 1 (3.7) | 1 (7.1) | 2 (4.9) |
| Participant responsibilities | |||
| Essential | 18 (66.7) | 12 (85.7) | 30 (73.2) |
| Neutral | 8 (29.6) | 0 (0.0) | 8 (19.5) |
| Non-essential | 1 (3.7) | 2 (14.3) | 3 (7.3) |
| Study risks | |||
| Essential | 18 (66.7) | 7 (50.0) | 25 (61.0) |
| Neutral | 8 (29.6) | 5 (35.7) | 13 (31.7) |
| Non-essential | 1 (3.7) | 2 (14.3) | 3 (7.3) |
| Study benefits | |||
| Missing | 0 | 1 | 1 |
| Essential | 19 (70.4) | 10 (76.9) | 29 (72.5) |
| Neutral | 6 (22.2) | 2 (15.4) | 8 (20.0) |
| Non-essential | 2 (7.4) | 1 (7.7) | 3 (7.5) |
| Alternative treatments | |||
| Missing | 0 | 1 | 1 |
| Essential | 13 (48.1) | 10 (76.9) | 23 (57.5) |
| Neutral | 8 (29.6) | 3 (23.1) | 11 (27.5) |
| Non-essential | 6 (22.2) | 0 (0.0) | 6 (15.0) |
| Insurance | |||
| Missing | 1 | 0 | 1 |
| Essential | 10 (38.5) | 10 (71.4) | 20 (50.0) |
| Neutral | 10 (38.5) | 2 (14.3) | 12 (30.0) |
| Non-essential | 6 (23.1) | 2 (14.3) | 8 (20.0) |
| Payments | |||
| Essential | 16 (59.3) | 8 (57.1) | 24 (58.5) |
| Neutral | 8 (29.6) | 2 (14.3) | 10 (24.4) |
| Non-essential | 3 (11.1) | 4 (28.6) | 7 (17.1) |
| Study costs | |||
| Missing | 0 | 1 | 1 |
| Essential | 16 (59.3) | 11 (84.6) | 27 (67.5) |
| Neutral | 7 (25.9) | 1 (7.7) | 8 (20.0) |
| Non-essential | 4 (14.8) | 1 (7.7) | 5 (12.5) |
| Voluntary nature of study | |||
| Missing | 0 | 1 | 1 |
| Essential | 23 (85.2) | 10 (76.9) | 33 (82.5) |
| Neutral | 4 (14.8) | 1 (7.7) | 5 (12.5) |
| Non-essential | 0 (0.0) | 2 (15.4) | 2 (5.0) |
| Data access by monitors | |||
| Missing | 0 | 1 | 1 |
| Essential | 5 (18.5) | 3 (23.1) | 8 (20.0) |
| Neutral | 2 (7.4) | 2 (15.4) | 4 (10.0) |
| Non-essential | 20 (74.1) | 8 (61.5) | 28 (70.0) |
| Confidentiality | |||
| Missing | 0 | 1 | 1 |
| Essential | 15 (55.6) | 6 (46.2) | 21 (52.5) |
| Neutral | 9 (33.3) | 2 (15.4) | 11 (27.5) |
| Non-essential | 3 (11.1) | 5 (38.5) | 8 (20.0) |
| Inform when changes to protocol | |||
| Missing | 0 | 1 | 1 |
| Essential | 6 (22.2) | 11 (84.6) | 17 (42.5) |
| Neutral | 10 (37.0) | 2 (15.4) | 12 (30.0) |
| Non-essential | 11 (40.7) | 0 (0.0) | 11 (27.5) |
| Contact information of investigators | |||
| Missing | 0 | 1 | 1 |
| Essential | 19 (63.0) | 11 (84.6) | 30 (75.0) |
| Neutral | 6 (22.2) | 0 (0.0) | 6 (15.0) |
| Non-essential | 2 (14.8) | 2 (15.4) | 4 (10.0) |
| Study termination | |||
| Missing | 0 | 2 | 2 |
| Essential | 6 (22.2) | 3 (25.0) | 9 (23.1) |
| Neutral | 6 (22.2) | 1 (8.3) | 7 (17.9) |
| Non-essential | 15 (55.6) | 8 (66.7) | 23 (59.0) |
| Study duration | |||
| Essential | 16 (59.3) | 9 (64.3) | 25 (61.0) |
| Neutral | 3 (11.1) | 2 (14.3) | 5 (12.2) |
| Non-essential | 8 (29.6) | 3 (21.4) | 11 (26.8) |